Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University Hospital, Montpellier
The multi-centre COVIDOC study will evaluate the efficacy and safety of the use of hydroxychloroquine (10 days) combined with azithromycin (5 days) compared to hydroxychloroquine (10 days) in the the clinical evolution by the ordinal scale of 7 points in adults hospitalized outside Intensive care unit with pneumonia caused by infection by the SARS-CoV2 virus in France.
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
18-75 years old SARS CoV-2 Infection confirmed by positive virologic test realised in the 96 h before randomization
Beginning of COVID-19 symptoms \< 10 days at the time of randomization
Presence of symptom(s) of COVID-19 : fever (température \> or = 37,5°C) or respiratory sign(s) (cough, breathing discomfort) or recent anosmia
Presence of TDM/radiographic signs or pneumonia
Hospitalization out of ICU for COVID with: moderate clinical form (no oxygenotherapy) or non critical severe form (oxygenotherapy)
You may not be if
Absence of signed informed consent
SpO2 \< 90 % ambient air or \< 94 % with oxygenotherapy \> or = 3l/min
Need of oxygenotherapy \> 6 l/min or mechanical ventilation
Need of hospitalization in ICU
ALAT/ASAT \> 5 LSN
Renal failure (eGFR \< 40 ml/min ) or dialysis
Pregnancy or breastfeeding
Retinopathy
Known deficit in G6PD
Cardiac rythm / lengthening QT disorders
QT space lengthening on ECG with QTc \> 450 ms
Concomitant treatment :citalopram, escitalopram, hydroxyzine, domperidone, pipéraquine, anti-arhythmic class IA \& III, antidepressive drugs,..
Clareo Health | Hydroxychloroquine Plus Azithromycin Versus Hydroxychloroquine for COVID-19 Pneumonia (COVIDOC Trial)
